Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.45 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24486589 | 0.96 | CTSL (0.42) | CTSLCAPN1CTSB | |
| SCHEMBL30001755 | 0.96 | CTSL (0.42) | CTSLCAPN1CTSB | |
| SCHEMBL24109107 | 0.96 | CTSL (0.42) | CTSLCAPN1CTSB | |
| Hydrochloric Acid SCHEMBL30001949 | 0.94 | CTSL (0.42) | CTSLCAPN1CTSB | |
| Trifluoroacetic Acid SCHEMBL30002552 | 0.89 | CTSL (0.43) | CTSLCAPN1CTSBCTSSCTSK | |
| SCHEMBL23824251 | 0.86 | CTSL (0.43) | CTSLCAPN1CTSBCTSSCTSK | |
| SCHEMBL23824248 | 0.86 | CTSL (0.43) | CTSLCAPN1CTSBCTSSCTSK | |
| SCHEMBL29609073 | 0.86 | — | — | |
| SCHEMBL25761960 | 0.85 | CTSL (0.43) | CTSLCAPN1CTSB | |
| SCHEMBL15985646 | 0.84 | CTSL (0.45) | CTSLCAPN1CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099424-A1 | Nitrile-Containing Antiviral Compounds | PFIZER INC. (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4516301-A2 | NITRILE-CONTAINING COMPOUNDS FOR USE AS MEDICAMENTS | Pfizer Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| EP-4166539-B1 | NITRILE-CONTAINING COMPOUNDS FOR USE AS MEDICAMENTS | PFIZER (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20230120254-A1 | Nitrile-Containing Antiviral Compounds | PFIZER INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-4166539-A1 | NITRILE-CONTAINING COMPOUNDS FOR USE AS MEDICAMENTS | Pfizer Inc. (US) | 2023-04-19 | — | — | EP | disclosed |
| US-11541034-B2 | Nitrile-containing antiviral compounds | PFIZER INC. (US) | 2023-01-03 | — | — | US | disclosed |
| EP-3953330-B1 | NITRILE-CONTAINING COMPOUNDS USEFUL AS ANTIVIRAL AGENTS FOR THE TREATMENT OF A CORONAVIRUS INFECTION | PFIZER (US) | 2022-10-12 | — | — | EP | disclosed |
| US-11452711-B2 | Nitrile-containing antiviral compounds | PFIZER INC. (US) | 2022-09-27 | — | — | US | disclosed |
| US-20220257563-A1 | Nitrile-Containing Antiviral Compounds | PFIZER INC. (US) | 2022-08-18 | — | — | US | disclosed |
| US-11351149-B2 | Nitrile-containing antiviral compounds | PFIZER INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20220142976-A1 | Nitrile-Containing Antiviral Compounds | PFIZER INC. (US) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220257563-A1 | Nitrile-Containing Antiviral Compounds | ACE2, NOS2, EIF2AK2 | CTSL 635/4885CAPN1 1185/4885CTSB 657/4885 |
| US-11452711-B2 | Nitrile-containing antiviral compounds | ACE2, NOS2, EIF2AK2 | CTSL 635/4885CAPN1 1185/4885CTSB 657/4885 |
| US-20230120254-A1 | Nitrile-Containing Antiviral Compounds | ACE2, NOS2, EIF2AK2 | CTSL 635/4885CAPN1 1185/4885CTSB 657/4885 |
| US-20250099424-A1 | Nitrile-Containing Antiviral Compounds | ACE2, NOS2, EIF2AK2 | CTSL 635/4885CAPN1 1185/4885CTSB 657/4885 |
| US-20220142976-A1 | Nitrile-Containing Antiviral Compounds | ACE2, NOS2, EIF2AK2 | CTSL 635/4885CAPN1 1185/4885CTSB 657/4885 |
| US-11541034-B2 | Nitrile-containing antiviral compounds | ACE2, NOS2, EIF2AK2 | CTSL 635/4885CAPN1 1185/4885CTSB 657/4885 |
| US-11351149-B2 | Nitrile-containing antiviral compounds | ACE2, NOS2, EIF2AK2 | CTSL 635/4885CAPN1 1185/4885CTSB 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.